

**ASX ANNOUNCEMENT**

22 May 2020

**Chairman and Director Appointment**

Probiotec Limited (ASX:PBP) ("**Company**") has today appointed Jonathan Wenig as a non-executive director of the company.

Mr Wenig is a partner at Arnold Bloch Leibler, a leading Australian commercial law firm. His practice and expertise spans the breadth of commercial and corporate law, including mergers and acquisitions, technology and financing. He is a trusted advisor to numerous active and innovative public companies - bringing his intellect and experience to bear not only in their corporate matters and acquisition activities, but across their legal affairs and strategic challenges and opportunities.

He has a wide breadth of business experience across a range of industry sectors, including internet, manufacturing, agriculture, retail, health and banking.

Mr Wenig is ranked as one of Australia's leading Corporate and M&A lawyers in the prominent legal sector publications, Chambers Asia Pacific and The Legal 500 Asia Pacific. He is also recognised by Best Lawyers® International in the area of corporate and M&A law and has been ranked by Doyle's Guide in the categories of private equity and corporate law.

Probiotec Chairman, Mr Geoff Pearce said "we are delighted to have Jonathan join the board of Probiotec. His experience, expertise and relationships are extremely impressive and we look forward to him providing a valuable contribution to our growing business".

Mr Wenig will join the board under a casual vacancy from 1 June 2020 and be eligible for re-election at the next Annual General Meeting.

The board is also pleased to advise that it has resolved to appoint Mr Sandy Beard to the role of Chairman from 1 July 2020 upon the retirement of the current chairman, Mr Geoff Pearce as per our previous announcement on the 8<sup>th</sup> April 2020.

The Company is continuing to search for an additional non-executive director and will provide further updates as and when appropriate.

**About Probiotec**

Probiotec Limited is a manufacturer, packer and distributor of a range of prescription and over-the-counter (OTC) pharmaceuticals, complementary medicines and consumer health products. The company owns three manufacturing facilities in Australia and distributes its products both domestically and internationally. Products are manufactured by Probiotec on behalf of a range of clients, including major international pharmaceutical companies.

Further details about Probiotec are available at [www.probiotec.com.au](http://www.probiotec.com.au)

**Authorised for release to the ASX by:**

Wes Stringer  
Managing Director  
Ph: (03) 9278 7555

**For further information contact:**

Wes Stringer  
Managing Director  
Ph: (03) 9278 7555